WEBINAR SERIES—Cardiometabolic Disease Pathophysiology and Novel Therapies

October 26, 2022
11 a.m. EDT

The unabated increase in cardiometabolic disease is a main reason why coronary heart disease remains the leading cause of death worldwide. Despite the effectiveness of lipid lowering therapy to treat coronary atherosclerosis, calcification remains a challenging clinical problem.

Lipid lowering therapy is highly effective in treating atherosclerosis, but statins and exercise have been shown to increase coronary artery calcification. Michael Sturek, MS, PhD, of Indiana University, will review data showing a predominance of intracellular calcium release in coronary smooth muscle cells that, in metabolic syndrome, decreases remarkably in swine and human cells.

Speaker

Michael Sturek, MS, PhD, a professor at Indiana University, has 35 years of experience in academia, teaching and conducting research on cardiometabolic disease. The general aim of Sturek’s research program is to understand cellular and molecular calcium signaling mechanisms for in vivo comorbidities in cardiometabolic disease. His research encompasses experimental approaches at all levels, from human tissue to whole animal, organ, tissue, cell and molecular.